ALIM

Alimera SciencesNasdaqGM:ALIM Stock Report

Market Cap

US$33.4m

7D

-13.3%

1Y

-14.1%

Updated

16 Sep, 2021

Data

Company Financials +
ALIM fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health1/6
Dividends0/6

ALIM Overview

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally.

Alimera Sciences Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Alimera Sciences
Historical stock prices
Current Share PriceUS$4.82
52 Week HighUS$3.82
52 Week LowUS$12.25
Beta1.61
1 Month Change-12.36%
3 Month Change-49.26%
1 Year Change-14.08%
3 Year Change-70.25%
5 Year Change-80.29%
Change since IPO-97.08%

Recent News & Updates

Aug 24
Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Why Alimera Sciences' (NASDAQ:ALIM) Earnings Are Weaker Than They Seem

Even though Alimera Sciences, Inc. ( NASDAQ:ALIM ) posted strong earnings recently, the stock hasn't reacted in a large...

Shareholder Returns

ALIMUS PharmaceuticalsUS Market
7D-13.3%-2.6%-0.6%
1Y-14.1%12.1%33.6%

Return vs Industry: ALIM underperformed the US Pharmaceuticals industry which returned 12.8% over the past year.

Return vs Market: ALIM underperformed the US Market which returned 33.7% over the past year.

Price Volatility

Is ALIM's price volatile compared to industry and market?
ALIM volatility
ALIM Beta1.61
Industry Beta0.64
Market Beta1

Stable Share Price: ALIM is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: ALIM's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2003135Rick Eiswirthhttps://www.alimerasciences.com

Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician offices, pharmacies, and hospitals through direct sales and distributors.

Valuation

Is Alimera Sciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ALIM ($4.82) is trading below our estimate of fair value ($18.23)

Significantly Below Fair Value: ALIM is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ALIM is good value based on its PE Ratio (16.5x) compared to the US Pharmaceuticals industry average (24.4x).

PE vs Market: ALIM is good value based on its PE Ratio (16.5x) compared to the US market (17.8x).


Price to Earnings Growth Ratio

PEG Ratio: ALIM's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: ALIM has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Future Growth

How is Alimera Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-77.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ALIM's earnings are forecast to decline over the next 3 years (-77.6% per year).

Earnings vs Market: ALIM's earnings are forecast to decline over the next 3 years (-77.6% per year).

High Growth Earnings: ALIM's earnings are forecast to decline over the next 3 years.

Revenue vs Market: ALIM's revenue (9.2% per year) is forecast to grow slower than the US market (9.7% per year).

High Growth Revenue: ALIM's revenue (9.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ALIM's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Alimera Sciences performed over the past 5 years?

39.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ALIM has a large one-off gain of $2.2M impacting its June 30 2021 financial results.

Growing Profit Margin: ALIM became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: ALIM has become profitable over the past 5 years, growing earnings by 39.4% per year.

Accelerating Growth: ALIM has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ALIM has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: Whilst ALIM's Return on Equity (39.42%) is high, this metric is skewed due to their high level of debt.


Financial Health

How is Alimera Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: ALIM's short term assets ($45.2M) exceed its short term liabilities ($10.3M).

Long Term Liabilities: ALIM's short term assets ($45.2M) do not cover its long term liabilities ($45.9M).


Debt to Equity History and Analysis

Debt Level: ALIM's debt to equity ratio (723.1%) is considered high.

Reducing Debt: ALIM's debt to equity ratio has increased from 281.7% to 723.1% over the past 5 years.

Debt Coverage: ALIM's debt is not well covered by operating cash flow (4.2%).

Interest Coverage: ALIM's interest payments on its debt are not well covered by EBIT (0.9x coverage).


Balance Sheet


Dividend

What is Alimera Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ALIM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ALIM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ALIM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ALIM's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ALIM's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.7yrs

Average management tenure


CEO

Rick Eiswirth (53 yo)

2.67yrs

Tenure

US$887,858

Compensation

Mr. Richard S. Eiswirth, Jr., also known as Rick, has been President of Alimera Sciences, Inc. since January 1, 2016 and its Chief Executive Officer and Director since January 2, 2019. He was Chief Financi...


CEO Compensation Analysis

Compensation vs Market: Rick's total compensation ($USD887.86K) is above average for companies of similar size in the US market ($USD548.10K).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ALIM's management team is considered experienced (2.7 years average tenure).


Board Members

Experienced Board: ALIM's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 37.6%.


Top Shareholders

Company Information

Alimera Sciences, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Alimera Sciences, Inc.
  • Ticker: ALIM
  • Exchange: NasdaqGM
  • Founded: 2003
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$33.375m
  • Shares outstanding: 6.92m
  • Website: https://www.alimerasciences.com

Number of Employees


Location

  • Alimera Sciences, Inc.
  • 6120 Windward Parkway
  • Suite 290
  • Alpharetta
  • Georgia
  • 30005
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/16 22:53
End of Day Share Price2021/09/16 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.